Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00070537" target="_blank" >RIV/65269705:_____/19:00070537 - isvavai.cz</a>

Result on the web

<a href="https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25444" target="_blank" >https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25444</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ajh.25444" target="_blank" >10.1002/ajh.25444</a>

Result language

angličtina

Original language name

Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program

Original language description

Two randomized, double-blind, placebo-controlled studies demonstrated responses (GREATER-THAN OR EQUAL TO50 000/μL) to fostamatinib in adults with long-standing immune thrombocytopenia (ITP). The long-term safety and efficacy of fostamatinib were evaluated in a follow-on, open-label extension (OLE) study. Patients received double-blind fostamatinib in the randomized trials, and responders continued the same dose, 100 to 150 mg BID, in the OLE study. Nonresponders received 100 mg BID for 4 weeks and could escalate to 150 mg BID at week 4. Endpoints included stable response, platelet count GREATER-THAN OR EQUAL TO50 000/μL at 4/6 biweekly (randomized trials) or 2/3 monthly visits (OLE), and overall response, GREATER-THAN OR EQUAL TO1 platelet count GREATER-THAN OR EQUAL TO50 000/μL during weeks 1 to 12. A total of 146 patients received fostamatinib including 123 in the OLE study. Median treatment duration was 6.7 months. Baseline median ITP duration was 8 years and median platelet count was 16 000/μL; prior treatments included thrombopoietic (TPO) agents (47%), splenectomy (35%), and rituximab (32%). Twenty-seven (18%) patients achieved a stable response with median duration of &gt;28 months and a median platelet count of 89 000/μL. Sixty-four (44%) patients achieved an overall response (including stable responders) with a median platelet count of 63 000/μL and a median response duration of &gt;28 months. Twenty-four of 71 (34%) patients who had failed TPO agents achieved overall responses to fostamatinib. The most common adverse events (AEs) were diarrhea, hypertension, nausea, epistaxis, and abnormal liver function tests. Most AEs were mild/moderate and resolved or were managed with dose reduction, dose interruption, and/or secondary medication. Almost half of the patients achieved an overall response, and most of these maintained their responses for &gt;2 years. No new or increased frequency of AEs was seen at up to 31 months of treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

American Journal of Hematology

ISSN

0361-8609

e-ISSN

—

Volume of the periodical

94

Issue of the periodical within the volume

5

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

546-553

UT code for WoS article

000468303900005

EID of the result in the Scopus database

2-s2.0-85062993134